PRN: 3D Bioprinting 2014-2024: Applications, Markets, Players - 3D Bioprinting Will Begin To Realize Its True Potential Within The Coming Decade

14/gen/2016 17:10:55 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

3D Bioprinting 2014-2024: Applications, Markets, Players - 3D Bioprinting Will Begin To Realize Its True Potential Within The Coming Decade


DUBLIN, Jan. 14, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "3D Bioprinting 2014-2024: Applications, Markets, Players" report to their offering.

This report provides a realistic timeline for the development and commercialisation of the 3D bioprinting technologies in what are largely heavily regulated application areas. A challenge matrix is presented, and evaluations of the addressable markets and their value provided. Forecasts are given for the period 2014-2025.

In addition to detailing each of the technologies currently employed, together with their state of commercialisation, future application areas are discussed including:

- Medical - tissue engineering, drug discovery, regenerative medicine, dental implants etc. - Cosmetic/personal consumer product screening - Biosensors Food and animal products

3D bioprinting constitutes a raft of technologies, commercial and not-yet commercial, which have the potential to significantly impact a number of major markets, including in vitro testing for more efficient drug discovery and toxicity testing of personal consumer products, as well as the clinical fields relating to implant/grafting of human tissue.

Though not yet employed within its addressable markets (current bioprinter sales and products are to research and development organisations only), the potential for rapid deployment in some areas already exists, subject to adequate funding being made available.

Drug discovery Drug discovery is a highly expensive process which in most cases will end in failure to gain regulatory clearance (see figure 1). The reason for this high failure rate is related to the lack of sufficiently accurate pre-clinical (prior to human volunteer) testing methodologies which have to date been limited to 2-dimensional human cell assays together with animal testing.

Different species can react to different drugs in very different ways, and further, 2-dimendional cell cultures behave very differently in terms of coalescence and proliferation compared to cells which inhabit a 3-dimensional environment. In short, humans are not 2-dimensional 70kg mice.

For some time therefore, medical researchers have sought means to mimic the 3-dimensional human tissue environment in the laboratory in an effort to make the drug discovery process more reliable, thereby (a) reducing complications associated to human clinical trials of novel drugs, (b) lowering the costs resulting from late-stage failures, (c) ensuring that dead-ends are abandoned quickly in order that attention can be focused on more promising avenues, and (d) shortening the drug discovery process timescale so that potentially life-saving drugs make it to the market as soon as possible.

Development of 3D assays has remained a challenge however, as the degree of precision required to emulate cell-to-cell communication in vivo (in the body) has proved elusive. Computer controlled 3D bioprinting, combined with curable bioinks, has now enabled the fabrication of 3D tissue, which moreover can survive for significantly longer periods of time compared to their 2D counterparts, enabling longer term impact of a novel drug on human tissue cultures to be analysed.

Key Topics Covered:



3. TECHNOLOGIES 3.1. Inkjet based bioprinting 3.2. Syringe/extrusion based bioprinting 3.3. Magnetic levitation bioprinting 3.4. Laser assisted bioprinting 3.5. Valve-based bioprinting 3.6. Technology summary


4.1. Medical

4.1.1. Drug screening

4.1.2. Regenerative medicine

4.1.3. Tissue replacement (avascular)

4.1.4. Tissue replacement (vascular)

4.2. Dental

4.3. Consumer/personal product testing

4.4. Biosensors

4.5. Food and animal product bioprinting

4.6. Bioinks

4.6.1. Cells

4.6.2. Growth factors/proteins

4.6.3. Support material

5. MARKETS 5.1. Market structure and key players 5.2. Value chain 5.3. Market barriers 5.4. Benefits


7. COMPANY INTERVIEWS 7.1. Biobots 7.2. Digilab Inc 7.3. Dyson 7.4. EFESTO LLC 7.5. EPSRC 7.6. Fraunhofer Additive Manufacturing Alliance 7.7. Fripp Design Ltd 7.8. MicroFab Technologies Inc 7.9. n3D Biosciences, Inc 7.10. nScrypt Inc 7.11. Organovo 7.12. regenHU Ltd 7.13. TeVido Biodevices 7.14. Viridis 3D

For more information visit

Media Contact:

Laura Wood, +353-1-481-1716,


blog comments powered by Disqus è un servizio offerto da Factotum Srl